Neuburgh Advisers’s Myriad Genetics MYGN Stock Holding History

Neuburgh Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$213K	Buy	7,440 +400	+6%	+$11.7K	0.01%	661
2019 Q2	$196K	Buy	7,040 +304	+5%	+$8.59K	0.01%	694
2019 Q1	$224K	Hold	6,736	–	–	0.01%	649
2018 Q4	$196K	Hold	6,736	–	–	0.01%	639
2018 Q3	$310K	Buy	6,736 +432	+7%	+$19.2K	0.01%	610
2018 Q2	$236K	Hold	6,304	–	–	0.01%	610
2018 Q1	$186K	Buy	6,304 +976	+18%	+$33K	0.01%	664
2017 Q4	$183K	Buy	5,328 +864	+19%	+$29.1K	0.01%	680
2017 Q3	$161K	Buy	4,464 +720	+19%	+$20.5K	0.01%	655
2017 Q2	$97K	Buy	3,744 +1,696	+83%	+$36K	﹤0.01%	738
2017 Q1	$39K	Buy	+2,048	New	+$36.3K	﹤0.01%	801

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Neuburgh Advisers's MYGN Position: Q3 2019 in Review

Neuburgh Advisers increased its Myriad Genetics (MYGN) stake by 5.7% in Q3 2019, buying an estimated $11.7K and bringing the position to 7,440 shares worth $213K. The position accounts for 0.01% of the portfolio, ranked #661.

Neuburgh Advisers first reported a position in MYGN in Q1 2017 and has held it in 11 quarters since. The position peaked at $310K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Neuburgh Advisers held 7,440 shares of Myriad Genetics worth $213K as of Q3 2019.
Neuburgh Advisers bought 400 Myriad Genetics shares in Q3 2019, an estimated $11.7K.
Myriad Genetics made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #661 holding.
Neuburgh Advisers first reported a position in Myriad Genetics in Q1 2017 and has held it in 11 quarters since.
Neuburgh Advisers's Myriad Genetics position peaked at $310K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.